Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 360 | $235.75 | $84,870.00 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,635 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.75 (range $235.63 to $235.82). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 533 | $234.56 | $125,020.48 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,995 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.56 (range $234.27 to $234.66). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 90 | $233.18 | $20,986.20 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,528 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 450 | $232.62 | $104,679.00 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,618 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.62 (range $232.06 to $233.05). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 270 | $230.98 | $62,364.60 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,068 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.98 (range $230.57 to $231.26). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 953 | $230.00 | $219,190.00 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,338 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $230.00 (range $229.52 to $230.31). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,156 | $239.23 | $755,009.88 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,291 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 249 | $245.82 | $61,209.18 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,447 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.82 (range $245.82 to $245.85). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 720 | $245.15 | $176,508.00 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,696 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $245.15 (range $244.77 to $245.51). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 540 | $244.08 | $131,803.20 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $244.08 (range $243.52 to $244.43). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,260 | $242.85 | $305,991.00 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,956 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.85 (range $242.45 to $243.32). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 720 | $242.04 | $174,268.80 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,216 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $242.04 (range $241.43 to $242.40). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,262 | $241.50 | $787,773.00 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,936 Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $248.73 | $99,492.00 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,198 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.73 (range $248.60 to $248.82). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,103 | $247.98 | $521,501.94 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,598 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.98 (range $247.55 to $248.50). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,821 | $246.88 | $449,568.48 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,701 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.88 (range $246.53 to $247.39). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,320 | $245.99 | $1,062,676.80 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,522 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.99 (range $245.50 to $246.45). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,426 | $245.05 | $839,541.30 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,842 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $245.05 (range $244.50 to $245.47). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $243.53 | $243,530.00 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,268 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.53 (range $242.88 to $243.86). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 12,215 | $240.95 | $2,943,204.25 |
DisclosureSEC source: 0001209191-20-008889 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,268 Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007519 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,483 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007519 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,160 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 15,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007519 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,360 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,941 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,767 Underlying: Common Stock · 1,941 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,156 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · derivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,156 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $232.87 | $93,148.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,190 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $232.87 (range $232.67 to $233.31). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,177 | $231.92 | $272,969.84 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,590 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.92 (range $231.54 to $232.50). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,306 | $231.25 | $302,012.50 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,767 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.25 (range $230.53 to $231.50). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 714 | $230.07 | $164,269.98 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,073 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.07 (range $229.48 to $230.47). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $228.89 | $114,445.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,787 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.89 (range $228.37 to $229.12). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,941 | $86.52 | $167,935.32 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,156 | $91.05 | $196,303.80 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-20-004251 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $235.00 | $1,175,000.00 |
DisclosureSEC source: 0001209191-20-004251 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,190 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-20-004251 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-20-003079 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $230.00 | $1,150,000.00 |
DisclosureSEC source: 0001209191-20-003079 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,190 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-20-003079 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-059883 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $225.00 | $1,125,000.00 |
DisclosureSEC source: 0001209191-19-059883 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-19-059883 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-058101 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $220.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-19-058101 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-19-058101 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057609 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $215.00 | $1,075,000.00 |
DisclosureSEC source: 0001209191-19-057609 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-19-057609 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 57 | $205.95 | $11,739.15 |
DisclosureSEC source: 0001209191-19-057148 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,942 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · derivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,708 Underlying: Common Stock · 1,942 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · derivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,156 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.